BridgeMD
Long-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease
EU CTIS ID: 2024-514602-31-00
What this study is testing
to determine whether treatment with aspirin, which inhibits cyclooxygenase-1 enzyme, can serve as a predictor of decreased susceptibility to SARS-CoV-2 infection and COVID-19 in patients with AERD. 2. to assess genetic features that might predict or attenuate SARS-CoV-2 infection on high-dose aspirin therapy.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- INCLUSION CRITERIA FOR AERD PATIENTS:* signed informed consent form * 18-70 years old AERD patients with baseline FEV1 of at least 70% of the predicted value on the challenge/desensitization day * no pregnancy, higly effective contraception must be used
- INCLUSION CRITERIA FOR HEALTHY CONTROL: * signed informed consent form * 18-70 years old and healthy condition * no asthma
You likely can't join if
- failure of the circulatory and respiratory system, liver, kidneys and other vital organs
- diabetes, cancer, systemic diseases of connective tissue, infectious diseases, coagulation disorders, active peptic ulcer disease, any active bleeding process.
- Use of drugs that interact with aspirin
- use of intoxicants, alcohol abuse, active and passive smoking
- pregnancy, lactation
- hypersensitivity to the active substance or any of the excipients
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.